113173
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
经动脉化疗栓塞联合索拉非尼可改善部分肝细胞癌伴肝外转移患者的生存率：一项多中心真实世界研究
Authors Yuan Y, Qiao Y, Zhu Y, Guo P, Gou J, Liu K, Wang L, Zhao S, Zhang Y, Liu Y, Wang E, Liu L
Received 30 October 2025
Accepted for publication 23 December 2025
Published 30 December 2025 Volume 2025:12 Pages 3049—3062
DOI https://doi.org/10.2147/JHC.S575739
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr David Gerber
Yue Yuan,1,* Yu Qiao,2,3,* Yejing Zhu,2,* Ping Guo,4 Jiakun Gou,1 Kai Liu,1 Linqian Wang,2,5 Shoujie Zhao,2 Yongchao Zhang,6 Yunjie Liu,1 Enxin Wang,1 Lei Liu2
1Department of Digestive Diseases, Air Force Hospital of Western Theater Command, PLA, Chengdu, People’s Republic of China; 2Department of Infectious Diseases, Xijing Hospital, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, People’s Republic of China; 3Department of Gastroenterology, Yanan University Affiliated Hospital, Yan’an, People’s Republic of China; 4Center for Disease Control and Prevention of Western Theater Command, PLA, Chengdu, People’s Republic of China; 5Northwest University Medical College, Xi’an, People’s Republic of China; 6Department of Medical Affairs, Air Force Hospital of Western Theater Command, PLA, Chengdu, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Enxin Wang, Department of Digestive Diseases, Air Force Hospital of Western Theater Command, PLA, Chengdu, 610083, People’s Republic of China, Email wangex0912@outlook.com Lei Liu, Department of Infectious Diseases, Xijing Hospital, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, 710032, People’s Republic of China, Email liulei84207@163.com
Aim: The prognosis of hepatocellular carcinoma with extrahepatic spread (HCC-EHS) remains poor. While systemic therapy is standard, intrahepatic progression often drives mortality. This study evaluated whether combining transarterial chemoembolization (TACE) with sorafenib (TACES) improves outcomes versus TACE alone in HCC-EHS.
Methods: In this multicenter, retrospective study, 423 HCC-EHS patients (Child-Pugh A) were categorized into TACE-alone (n = 294) or TACES (n = 129) groups. The primary endpoint was overall survival (OS). Inverse probability of treatment weighting (IPTW) was used to adjust for confounding. Radiological response was assessed per mRECIST.
Results: After IPTW adjustment, the TACES group demonstrated significantly superior tumor response, with higher objective response (33.3% vs 16.4%, p = 0.004) and disease control rates (63.2% vs 46.3%, p = 0.008) compared to the TACE-alone group. This translated into a significant survival benefit, with a median OS of 10.4 months for TACES versus 7.0 months for TACE alone (IPTW-adjusted hazard ratio: 0.68; 95% CI: 0.52– 0.88; p = 0.004). The survival advantage remained consistent in landmark analyses. Subgroup analyses indicated that the absolute benefit from combination therapy was most pronounced in patients with high intrahepatic tumor burden and preserved liver function.
Conclusion: This real-world study demonstrates that in carefully selected patients with HCC-EHS, a combination of TACE and sorafenib provides significantly better tumor control and survival outcomes than TACE monotherapy. These findings suggest that an integrated therapeutic strategy, which aggressively manages the intrahepatic disease in conjunction with systemic therapy, can improve outcomes in this challenging-to-treat population and warrants validation in prospective studies.
Keywords: hepatocellular carcinoma, transarterial chemoembolization, sorafenib, survival
1Department of Digestive Diseases, Air Force Hospital of Western Theater Command, PLA, Chengdu, People’s Republic of China; 2Department of Infectious Diseases, Xijing Hospital, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, People’s Republic of China; 3Department of Gastroenterology, Yanan University Affiliated Hospital, Yan’an, People’s Republic of China; 4Center for Disease Control and Prevention of Western Theater Command, PLA, Chengdu, People’s Republic of China; 5Northwest University Medical College, Xi’an, People’s Republic of China; 6Department of Medical Affairs, Air Force Hospital of Western Theater Command, PLA, Chengdu, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Enxin Wang, Department of Digestive Diseases, Air Force Hospital of Western Theater Command, PLA, Chengdu, 610083, People’s Republic of China, Email wangex0912@outlook.com Lei Liu, Department of Infectious Diseases, Xijing Hospital, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, 710032, People’s Republic of China, Email liulei84207@163.com
Aim: The prognosis of hepatocellular carcinoma with extrahepatic spread (HCC-EHS) remains poor. While systemic therapy is standard, intrahepatic progression often drives mortality. This study evaluated whether combining transarterial chemoembolization (TACE) with sorafenib (TACES) improves outcomes versus TACE alone in HCC-EHS.
Methods: In this multicenter, retrospective study, 423 HCC-EHS patients (Child-Pugh A) were categorized into TACE-alone (n = 294) or TACES (n = 129) groups. The primary endpoint was overall survival (OS). Inverse probability of treatment weighting (IPTW) was used to adjust for confounding. Radiological response was assessed per mRECIST.
Results: After IPTW adjustment, the TACES group demonstrated significantly superior tumor response, with higher objective response (33.3% vs 16.4%, p = 0.004) and disease control rates (63.2% vs 46.3%, p = 0.008) compared to the TACE-alone group. This translated into a significant survival benefit, with a median OS of 10.4 months for TACES versus 7.0 months for TACE alone (IPTW-adjusted hazard ratio: 0.68; 95% CI: 0.52– 0.88; p = 0.004). The survival advantage remained consistent in landmark analyses. Subgroup analyses indicated that the absolute benefit from combination therapy was most pronounced in patients with high intrahepatic tumor burden and preserved liver function.
Conclusion: This real-world study demonstrates that in carefully selected patients with HCC-EHS, a combination of TACE and sorafenib provides significantly better tumor control and survival outcomes than TACE monotherapy. These findings suggest that an integrated therapeutic strategy, which aggressively manages the intrahepatic disease in conjunction with systemic therapy, can improve outcomes in this challenging-to-treat population and warrants validation in prospective studies.
Keywords: hepatocellular carcinoma, transarterial chemoembolization, sorafenib, survival